Related Experiment Video
Updated: Jul 15, 2025
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.3K
Utility of Stereotactic Body Radiation Therapy in Establishing Local Control for Patients With Invasive Breast Cancer
Ewa Zabrocka1, Simran Polce2, John D Roberson3
1Department of Radiation Oncology, Stony Brook University, Stony Brook, NY.
International Journal of Radiation Oncology, Biology, Physics
|October 4, 2023
Summary
Stereotactic body radiation therapy (SBRT) offers good local control for primary breast cancer (BC) in patients unsuitable for surgery. This well-tolerated treatment shows promise, though further research into regional and distant control is needed.
Area of Science:
- Oncology
- Radiation Oncology
- Breast Cancer Research
Background:
- Surgery is the standard treatment for breast cancer (BC).
- For patients unable to undergo surgery, maintaining local control (LC) of the primary tumor is critical.
- Stereotactic body radiation therapy (SBRT) is explored as an alternative for these patients.
Purpose of the Study:
- To evaluate the efficacy and tolerability of SBRT for primary breast cancer in nonsurgical candidates.
- To assess local control (LC) and overall survival (OS) rates following SBRT.
- To document acute and late toxicities associated with SBRT in this population.
Main Methods:
- A cohort of 21 nonsurgical patients with primary BC received SBRT (40 Gy/5 fractions) between 2015-2022.
- Data included retrospective and prospective analyses, with follow-up imaging and toxicity assessments (CTCAE v5).
- Kaplan-Meier methods were used to estimate LC and OS.
Main Results:
- SBRT demonstrated significant tumor size and SUV reduction post-treatment.
- Estimated LC rates were high: 100% at 6 months and 93.3% at 12-36 months.
- Overall survival rates were 85.7% at 6 months and 63.8% at 24-36 months, with manageable acute toxicities (G1-G3).
Conclusions:
- Definitive SBRT provides effective local control and is well-tolerated in nonsurgical breast cancer patients.
- The study highlights the potential of SBRT as a primary treatment option.
- Further investigation is warranted to enhance regional and distant disease control strategies.
